ORGANOIDS

CancerTools.org: The home for cancer research tools

PATIENT-DERIVED TUMOUR ORGANOIDS

Organoids are unique self-organising 3D microscopic structures derived from cells that represent a physiologically relevant in vitro model systems as they preserve the genomic, physiological characteristics and multicellularity of the equivalent in vivo tissue

Available cancer patient-derived organoids (PDOs) are 3D in vitro multicellular models established from a range of human tumour tissues
Represent a novel in vitro platform for basic biological research and potential applications in drug testing and molecular medicine
Use in various applications can complement existing experimental models

Prof. Motoki Takagi and his group from Fukushima Medical University (FMU) have used an independently developed method to establish F-PDOs
Recapitulate characteristics of in vivo tumours
Employed protocol does not involve enzyme treatment of the clinical material or use of extracellular matrix – the F-PDOs are cultured in suspension

Extensively characterised
Comprehensive gene expression, whole-exome sequencing and morphological analyses confirm the F-PDOs retain parental tissue characteristics for extended period of time in culture and after cryopreservation
Can be employed prior to using high-cost and time-consuming in vivo models such as patient derived xenografts (PDXs)

RLUN21_herceptin only_3h_10bai - with text-2

Key Features

Preserve parental tissue genetic profile and morphology: various characterisation tests confirm F-PDOs retain parental tissue genetic profile and morphology
Amenable to extended culture duration: genetically and phenotypically stable for 6 -12 months in culture and after cryopreservation
Suspension culture: no extracellular matrix required
In vivo tumorigenesis: suitable for PDX mouse development - gene expression profiles of the xenografts are similar to those of their source F-PDOs and tissues
Suitable for various assays: F-PDOs can be used to establish high-throughput assays to evaluate anticancer agents and antibodies
Well-characterized with annotation data: the organoids have been characterised using comprehensive gene expression, whole-exome sequencing and morphological analyses

Applications

Disease modelling
Anticancer agents discovery and development
Immuno-oncology assays
Compounds’ safety and toxicity testing

Explore the organoids currently available by cancer type:

Bile duct cancer	Breast cancer	Cervical cancer
Colorectal cancer	Esophageal cancer	Fallopian tube cancer
Gastric cancer	Kidney cancer	Lung cancer
Ovarian cancer	Pancreatic cancer	Peritoneal cancer
Skin cancer	Uterine cancer